June 3, 2021
Anivive Highlighted in Scientific American Article on Breakthrough Fungal Vaccine
May 26, 2021
Anivive Announces Collaboration with MWI Animal Health to Provide Veterinarians with the Newest Lymphoma Treatment for Dogs
January 21, 2021
Anivive Announces FDA Conditional Approval of LAVERDIA™-CA1 (verdinexor) - the First and Only Oral Tablet to Treat Lymphoma in DogsView all press releases
June 1, 2021
Deadly Fungi Are the Newest Emerging Microbe Threat All Over the World
Anivive's work with Dr. John Galgiani and his research team at the Valley Fever Center for Excellence at the University of Arizona College of Medicine is gaining attention as the threat of systemic fungal diseases escalates globally.
April 12, 2021
Anivive sprints to market with pet chemotherapy
Anivive Lifesciences Inc. is taking its first pet-specific drug to market after 3.5 years and $5 million in research and development costs.
Orange County Business Journal
January 18, 2021
FDA endorses canine epilepsy and lymphoma drugs
Medications from Pegasus Laboratories and Anivive Lifesciences earned conditional approvals.
Today’s Veterinary BusinessRead More
August 31, 2020
Cats point the way to potential COVID-19 remedies
Anivive Lifesciences, is working on a COVID-19 antiviral drug that’s inspired by cats, and it has new preclinical research findings to back up the project.
June 9, 2019
A drugs life: How David Bruyette’s biotech startup is changing the way veterinary products come to market
Anivive Lifesciences starts with unmet therapeutic needs and employs high-tech research methods to identify compounds that could meet those needs.
Our financial statement audits have been performed to Public Company Accounting Oversight Board (PCAOB) standards. These standards set the independence and audit requirements for the auditors, the level of financial reporting by the Company and are required for publicly held companies.
Audited Financial Statements